Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EN Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors
L01EN03 Infigratinib
D11611 Infigratinib phosphate (USAN)
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Infigratinib
D11611 Infigratinib phosphate (USAN)
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG03208 FGFR inhibitor
DG03062 Infigratinib
D11611 Infigratinib phosphate
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
FGFR family
FGFR1 (CD331)
D11611 Infigratinib phosphate (USAN)
FGFR2* (CD332) [HSA_VAR:2263v22263v1]
D11611 Infigratinib phosphate (USAN)
FGFR3 (CD333)
D11611 Infigratinib phosphate (USAN)
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11611
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11611
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D11611
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG03208 FGFR inhibitor
DG03062 Infigratinib